ELSEVIER

Contraception
2000;61:407–408

Author Index
Volume 61
January–June 2000

Abdalla, K., 187
Åberg, H., 265
Adekunle, A. O., 61, 139
Aisien, A. O., 283
Ajossa, S., 259
Albrecht, G., 309
Alvarez, F., 131, 187, 199
Amankwah-Poku, A., 287
Amory, J. K., 29
Arboleda, C., 309
Arowojolu, A. O., 139
Aslan, D., 359
Athayde, C., 61
Atta, G., 61

Bailon, R., 309
Barbato, M., 253
Bardin, C. W., 341
Barlow, W. E., 385
Bassol, S., 309
Bastidas, J. M., 395
Baveja, R., 113
Becker, B. J., 29
Beier, S., 317
Beksinska, M. E., 271
Beltran-Garcia, C., 99
Beltran-Garcia, M. J., 99
Bertan, M., 359
Biswas, A., 187
Blackwell, R., 217
Blanchard, K., 145
Blumenthal, P., 9
Boonstra, H., 9
Borgatta, L., 77
Brache, V., 131, 187, 199
Brynhildsen, J., 265
Bucheli, R., 309
Buckshee, K., 113
Bugalho, A., 47
Byström, B., 265

Callahan, M., 205
Campbell-Heider, N., 83
Campodonico, I., 187
Cano, E., 395
Carneiro de Oliverira, H., 309
Carr, B., 217
Carranza, S., 309
Castañeda, A., 309
Celis, C., 309
Chada, E., 309
Chen, Z.-W., 61
Civic, D., 385
Clarke, S., 225
Cochon, L., 199
Coutinho, E. M., 61, 277
Cravioto, M. C., 309
Creinin, M. D., 29
Cromie, M. A., 51
Croxatto, H., 199

Darney, P., 187, 351
Das, K., 113
Das, S. K., 113
Dasmahapatra, R., 225
Datey, S., 113
D'Aurea Abranches, A., 277
David, E., 47
D'Cruz, O. J., 69
de Andrade, M. E., 309
de Barros Leal, W., 277
de Mello, N. R., 309
de Melo, K., 309
Diaz, S., 187
Diczfalusy, E., 3
Dominguez, L., 9
Doncel, G., 235
Duran, V., 9
Durand, M., 309

Eisinger, S. H., 41
Ellertson, C., 145
Elomaa, K., 131
Emuveyan, E., 61
Espinosa, A., 99
Etchepareborda, J. J., 317

Fakokunde, A. F., 139
Faúndes, A., 47, 199
Feldblum, P. J., 379
Felix, J. C., 231
Fielding, S. L., 41
Floris, S., 259
Fraser, I. S., 131, 241
Freedman, L., 351
Frezieres, R. G., 205, 369
Fugarolas, J., 309
Fuller, L., 41

Gamble, V. N., 9
Gaona, R., 309
Garza-Flores, J., 309
Gaur, L. N., 113
Glantz, J. C., 83
Glantz, S., 83
Glover, E. K., 287
Goldberg, E., 235
Goldzieher, J. W., 27
Gomez, P., 309
Gopalan, S., 113
Goswami, A., 113
Gu, Z.-P., 61
Guerriero, S., 259
Guida, M., 253
Gunn, S., 231
Gupta, N. K., 113
Gupta, R. N., 113
Gurucharri, C., 309
Guzman-Serani, R., 379

Hammar, M., 265
Hays, M., 287, 379
Hazra, M. N., 113
Herrera, N., 99
Hidalgo, I., 309
Hippolito, S. B., 277
Hodoglugil, N. N. S., 359
Hogg, B., 365
Holma, P., 187
Hovelli, J., 309
Hu, J., 91

Ichikawa, L., 385
Imade, G. E., 283

Jaakkola, U.-M., 401
Jackson, R., 351
Jain, J. K., 195
Jayakrishnan, A., 329
Johansson, E. D. B., 241

Kahn, J. G., 29
Kaplan-Kraicer, R., 341
Kaunitz, A. M., 295
Kaye, A. M., 231
Keller, P. J., 365
Kiriwat, O., 187
Kleinschmidt, I., 271
Kodkany, B. S., 113
Kumar, S., 113
Kumary, T. V., 329
Kuohung, W., 77

Lacarra, M., 131
LaCroix, A. Z., 385
Ladipo, O. A., 139

© 2000 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/00/$–see front matter
PII S0010-7824(00)00126-8

Contraception
2000;61:407–408

Lähteenmäki, P., 131
Lal, A. V., 329
Latha, M. S., 329
Lebeda, E., 365
Letterie, G. S., 391
Li, H.-q., 323
Lopez, C., 309
Lovvorn, A., 287
Lunelle Study Group, 51
Lynch, M., 217

Macaluso, M., 217
Maclsaa, L., 29
Mahanta, H. C., 335
Mahony, M. C., 235
Maile, M. H., 51
Mannias, M., 259
Martens, M., 205
Massai, R., 199
Mati, J., 61
Mauck, C., 205
McIntyre, J., 271
Meinzen-Derr, J., 217
Melis, G. B., 259
Mendez, J., 309
Merki-Feld, G. S., 365
Mifepristone Clinical Trials Group, 225
Minehan, E., 241
Mishell, D. R., Jr, 131
Mishell, D. R., Jr., 1, 187, 195, 199
Mocumbi, S., 47
Montgomery, M., 217
Moo-Young, A. J., 199
Mora, N., 395
Morais, K., 277

Nappi, C., 253
Nash, H. A., 131
Nassa de Souza, R., 277
Nerquaye-Tetteh, J., 287
Neto, J. S. P., 277
Neuhaus, J., 29
Nikkanen, V., 401
Nnana, O. U., 283

Ogura, T., 99
Olavide, R., 309
Olkin, I., 29
Orrù, M., 259
Ota, F., 195
Ott, S. M., 385
Otubu, J., 61

Paler, R. J., Jr., 231
Palomba, S., 253
Paoletti, A. M., 259
Parada, L. M., 309
Parejarios, J., 309
Parsey, K. S., 105
Pasquale, S., 187
Pavez, M., 187
Perez-Zapata, A. J., 99
Pettifor, A. E., 271
Phaosavadi, S., 281
Phupong, V., 347
Pies, C., 9
Pong, A., 105
Pruksananonda, K., 347

Raymond, E., 287
Rees, H. V., 271
Reidenberg, M. M., 61
Reinprayoon, D., 281
Reyes-Marquez, R., 309
Rice, K., 235
Roark, M., 217
Robbins, A., 199
Roy, M., 113

Sagay, A. S., 283
Salvatierra, A. M., 199
Sang, G.-W., 61
Santoyo, S., 309
Sarma, H. N., 335
Saxena, B. N., 113
Saxena, N. C., 113
Schaff, E., 83
Schaff, E. A., 41
Schechter, J., 187
Scholes, D., 385
Schwarz, E. B., 351
Segal, S. J., 61
Shalgi, R., 341
Shinnar, N., 341
Shochet, T., 145
Simpson, D. R., 231
Singh, R., 113
Sivin, I., 187
Smith, K. R., 121
Söderström, K.-O., 401
Sokal, D. C., 379
Spinola, P., 277
Sreekumar, R., 329
Stadalius, L. S., 41
Stanford, J. B., 121
Stringer, E. M., 217
Stubblefield, P., 77

Succar, J., 309
Sueblinvong, T., 347
Sujaya Kumari, C. N., 113

Taneepanichskul, S., 281, 347
Taylor, D., 205
Thomas, D. B., 323
Tomaz, G., 277
Tommaselli, G. A., 253
Triratanachat, S., 347
Trujillo, L., 309
Trussell, J., 145
Tuusa, S., 401

Uckun, F. M., 69
Ujah, I. A. O., 283
United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research and Development and Research Training in Human Reproduction/Task Force on Post/Ovulatory Methods for Fertility Regulation, 303

Vacca, A. M. B., 259
Vazquez, L., 309
von Kesserü, E., 317
von Schoultz, B., 265

Wajszczuk, C. P., 51
Walsh, T., 205
Walsh, T. L., 369
Wan, L., 187
Waurzyniak, B., 69
Weisberg, E., 131, 241
Westhoff, C., 225
Wikinski, R., 317
Wildemeersch, D., 91
Winikoff, B., 225
World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives, 323
Wreje, U., 265
Wu, S., 91

Yadav, S. C., 113
Yassle, M. E., 309
Yiv, S. H., 69
Yoshida, C. K., 385
Zaveri, K., 113
Zipper, J., 379

ELSEVIER

Contraception
2000;61:409–412

Subject index
Volume 61
January–June 2000

Acceptability,
  baggy latex condom, 217
  latex condoms, 205, 369
  non-latex condom, 369
  polyurethane condom, 369
  synthetic material condom, 369
  Tactylon condoms, 205
Actinomyces-like organisms in Papanicoloau smears, IUD users, 365
Actinomycotic infection, uterine perforation with Lippes loop; case report, 347
Alesse®, effect on ovarian follicular activity, 195
Anabolic state, effect of ethinyl estradiol + desogestrel, 265
Analgesia use, medical abortion, 225
Anordiol, effect on pregnancy (rat), 341
Anti-HIV and contraceptive agent, zidovudine derivative (mouse), 69
Attitudes, knowledge and use, emergency contraception, 145
Avanti™ condoms, acceptability, 369

Bacterial vaginosis, IUD use, 359
Baggy latex condom, safety and acceptability, 217
Biodegradable drug delivery matrix, progesterone-loaded casein microspheres (rabbit), 329
Birth spacing method, complete breastfeeding and lactational amenorrhea, 253
Bone density, effect of estradiol valerate + norethisterone enanthate, 317
Bone metabolism, 265
Bone mineral density, OC use, 77
Bone resorption, effect of ethinyl estradiol + gestodene, 259
Boom and bust phenomenon, contraceptive revolution, 9
Breakage rate, condoms, 205, 369
Breastfeeding and lactational amenorrhea, birth spacing method, 253
Bust without boom, contraceptive revolution, 27

Casein microspheres loaded with progesterone, intramuscular injection (rabbit), 329
Cervical cancer risk, tubal ligation, 323
Chlamydia infection, relationship to inflammation score of Papanicolaou smear, 231
Cholesterol metabolism, effects of ethinyl estradiol and norgestrel (rat), 391
Clinical experience, estradiol valerate + norethisterone enanthate, 309
Clinical trial,
  ethinyl estradiol + drospirenone, 105
  GyneFix, 91
  injectable estradiol enanthate + dihydroxyprogesterone acetophenide, 277
  TCu 380A, 91
  triphasic ethinyl estradiol + desogestrel, 295
  triphasic ethinyl estradiol + norethindrone, 295
Collagen metabolism, effect of ethinyl estradiol + desogestrel, 265
Composite root extract, effect on ovary and endometrium (rat), 335
Continuation rates, Norplant implants, 83
Contraceptive and anti-HIV agent, zidovudine derivative (mouse), 69
Contraceptive choice evaluation, method-mix approach, 113
Contraceptive revolution,
  boom and bust phenomenon, 9
  bust without boom, 27
  editorial, 3
Contraceptive, low-estrogen, 259
Copper, effect on uterine cells, 99
Copper corrosion, simulated uterine solution, 395
Copper oxidation, copper-bearing IUD, 99
Copper-bearing IUD, copper oxidation, 99
Creighton Model Fertility Care System, natural family planning, 121
Cyclessa™, clinical trial, 295

Depressive symptoms, DMPA users, 385
Desolett®, effect on collagen metabolism, 265
DMPA (depot-medroxyprogesterone acetate)
DMPA use in older women, 281
DMPA users, depressive symptoms, 385

Efficacy,
  gossypol, 51
  medical abortion, 29
  Norplant capsule implants, 187
  repeated postcoital levonorgestrel, 303
Emergency contraception,
  knowledge and willingness to use, 351
  knowledge, use and attitudes, 145
  review, 145
  service delivery aspects, 145
  social science aspects, 145
Emergency contraception programs, 145
Emergency contraceptive pills,
  study of provision approaches, 287
  use by spermicide users, 287
Endometrium, effect of composite root extract (rat), 335
Epididymal application, levonorgestrel (rat), 401

© 2000 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/00/$–see front matter
PII S007824(00)00127-X

Estradiol cypionate + medroxyprogesterone acetate,
effect on lipid profiles, 51
effect on ovarian follicular activity, 195
Estradiol enanthate + dihydroxyprogesterone acetophenide, clinical study, 277
Estradiol valerate + norethisterone enanthate,
clinical experience, 309
effect on bone density, 317
effect on lipid metabolism, 317
premenopausal contraception, 317
Ethinyl estradiol, effect on cholesterol metabolism (rat), 391
Ethinyl estradiol + desogestrel,
clinical trial, 295
effect on anabolic state, 265
effect on collagen metabolism, 265
Ethinyl estradiol + drospirenone, clinical study, 105
Ethinyl estradiol + gestodene, effect on bone resorption, 259
Ethinyl estradiol + levonorgestrel, effect on ovarian follicular activity, 195
Ethinyl estradiol + Nestorone-releasing vaginal ring, effect on vaginal epithelium, 131
Ethinyl estradiol + norethindrone,
clinical trial, 295
effect on lipid profiles, 51
Ethinyl estradiol + norethindrone-releasing vaginal ring, effect on vaginal epithelium, 131

Female condom,
reuse, 271
structural integrity, 271

Gossypol,
effect on spermatogenesis, 61
safety and efficacy, 61
GyneFix, clinical trial, 91

Hematological indices, effect of levonorgestrel, 283
HIV (human immunodeficiency virus)

Implant contraceptive,
levonorgestrel, 83, 187, 241, 283
Nestorone, 199, 241
nomegestrol acetate, 139
Inflammation score of Papanicolaou smear, relationship to Chlamydia infection, 231
Informed contraceptive choice, method-mix approach, 113
Injectable contraceptive,
depot-medroxyprogesterone acetate, 277, 385
estradiol cypionate + medroxyprogesterone acetate, 51, 195
estradiol enanthate + dihydroxyprogesterone acetophenide, 277
estradiol valerate + norethisterone enanthate, 309, 317
Intrauterine device (IUD),
boom and bust phenomenon, 9
GyneFix, 91
levonorgestrel-releasing, 365
Lippes loop, 347
Multiload Cu 375, 365
Nova-T, 317
TCu 380A, 91
Intravaginal studies, zidovudine derivative (mouse), 69
IUD (intrauterine device)
IUD use, sexually transmitted disease, 359
IUD users, incidence of actinomyces-like organisms, 365

Knowledge, emergency contraception, 351
Knowledge, use and attitudes, emergency contraception, 145

Lactational amenorrhea, birth spacing method, 253
Latex condoms,
acceptability, 369
breakage and slippage rates, 205, 369
Levonorgestrel,
effect of epididymal application (rat), 401
effect on menstrual and hematological indices, 283
post-testicular contraception (rat), 401
repeated postcoital use, 303
Levonorgestrel-releasing IUD, incidence of actinomyces-like organisms, 365
Lipid profiles,
effect of estradiol cypionate + medroxyprogesterone acetate, 51
effect of estradiol valerate + norethisterone enanthate, 317
effect of nomegestrol acetate, 139
effect of triphasic ethinyl estradiol + norethindrone, 51
Lippes loop, uterine perforation and actinomycotic infection; case report, 347
Low-dose OC use, effect on bone mineral density, 77
Lunelle™, clinical trial, 51, 195

Male contraceptive pill, gossypol, 81
Medical abortion,
efficacy, 29
mifepristone + misoprostol, 41
misoprostol, 47
narcotic analgesia use, 225
Menstrual blood loss, effect of progestogen-only contraceptives, 241
Menstrual indices, effect of levonorgestrel, 283
Mesigna®,
clinical experience, 309
premenopausal contraception, 317
Meta-analysis, efficacy of medical abortion, 29
Method-mix approach, contraceptive choice evaluation, 113
Mifepristone + misoprostol, medical abortion, 41

Misoprostol, medical abortion, 47
Multiload Cu 375, incidence of actinomyces-like organisms, 365

Natural family planning, Creighton Model Fertility Care System, 121, 253
Nestorone® (16-methylene-17α-acetoxy-19-norpregnene-3,20-dione)
Nestorone implants,
  effect on menstrual blood loss, 241
  effect on ovarian function, 199
Nestorone vaginal ring,
  effect on menstrual blood loss, 241
  effect on vaginal epithelium, 131
Nomegestrol acetate, effect on lipid profiles, 139
Non-latex condom, acceptability, 369
Non-surgical female sterilization, quinacrine pellets, 379
Norgestrel, effect on cholesterol metabolism (rat), 391
Norplant capsule implants, effectiveness, 187
Norplant® implants,
  boom and bust phenomenon, 9
  effect on menstrual and hematological indices, 283
  effect on menstrual blood loss, 241
  use by urban women, 83
Nova-T, premenopausal contraception, 317

OC (oral contraceptive)
OC use, effect on bone mineral density, 77
Older women, use of DMPA, 277
Oral contraceptive (OC),
  boom and bust phenomenon, 9
  ethinyl estradiol + desogestrel, 265
  ethinyl estradiol + drospirenone, 105
  ethinyl estradiol + gestodene, 259
  ethinyl estradiol + levonorgestrel, 195
  triphasic ethinyl estradiol + desogestrel, 295
  triphasic ethinyl estradiol + norethindrone, 51, 295
  Ortho-Novum® 7/7/7, clinical trial, 51, 295
Ovarian follicular activity,
  effect of estradiol cypionate + medroxyprogesterone acetate, 195
  effect of ethinyl estradiol + levonorgestrel, 195
Ovarian function, effect of Nestorone, 199
Ovary, effect of composite root extract (rat), 335
Oxidation products, copper-bearing IUD, 99

Papanicolaou smear,
  incidence of actinomyces-like organisms, 365
  relationship of inflammation score to Chlamydia infection, 231
Polyurethane condom, acceptability, 369
Post-testicular contraception, effect of levonorgestrel (rat), 401
Postcoital levonorgestrel, efficacy and side effects, 303
Pregnancy, effect of anordiol (rat), 341
Pregnancy rate, following sterilization with quinacrine pellets, 379
Premenopausal contraception, estradiol valerate + norethisterone enanthate, 317
Progesterone-loaded casein microspheres, intramuscular injection (rabbit), 329
Progestogen-only contraceptives, effect on menstrual blood loss, 241
Provision approaches, emergency contraceptive pills, 287
Pyridinium cross-links, 259

Quinacrine tubal sterilization, effectiveness, 379

Release profile, progesterone-loaded casein microspheres (rabbit), 329
Reuse, female condom, 271

Safety,
  baggy latex condom, 217
  gossypol, 61
  latex condoms, 205
  Tactylon condoms, 205
Service delivery aspects, emergency contraception, 145
Sexually transmitted disease, IUD use, 379
Side effects, repeated postcoital levonorgestrel, 303
Simulated uterine solution, copper corrosion, 395
Slippage rate, condoms, 205
Social science aspects, emergency contraception, 145
Soft tubing Norplant implants, effectiveness, 187
Sperm functional capacity assay (baboon), 235
Sperm-zona pellucida binding assay (baboon), 235
Spermatogenesis, effect of gossypol, 61
Spermicide users, use of emergency contraceptive pills, 287
Sterilization, quinacrine pellets, 379
Structural integrity, female condom, 271
Synthetic material condom, acceptability, 369

Tactylon™ condoms, breakage and slippage rates, 205
TCu 380A, clinical trial, 91
Termination rates, Norplant implants, 83
Thirty years of Contraception, editorial, 1
Trojan-Enz™ condom, acceptability, 369
Tubal ligation, risk of cervical cancer, 323
Tubal sterilization, quinacrine pellets, 379

Uniplant® implant, effect on lipid profiles, 139
Urban women, use of Norplant implants, 83
Use, knowledge and attitudes, emergency contraception, 145
Uterine cells, effect of copper-bearing IUD, 99
Uterine perforation with Lippes loop, actinomycotic infection; case report, 347

Contraception
2000;61:409–412

Vaginal epithelium, effect of vaginal rings use, 131
Vaginal ring,
releasing ethinyl estradiol + Nestorone, 131
releasing ethinyl estradiol + norethindrone acetate, 131
releasing Nestorone, 131, 241
Vaginal rings use, effect on vaginal epithelium, 131

Willingness to use, emergency contraception, 351

Yasmin, clinical study, 105

Zidovudine derivative,
dual-function topical microbicide (mouse), 69
intravaginal administration (mouse), 69